Tag: Pieris Pharmaceuticals

May 26, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Sesen Bio Up 40 Percent

Which NASDAQ biotech and pharma stocks were up last week? We examine the top five gainers and what may have...
November 7, 2018

Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other...
September 4, 2018

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy

Pieris Pharmaceuticals (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced...
June 5, 2018

10 Top Immuno-Oncology Companies

One of the most highly anticipated methods to fight cancer is the immuno-oncology (I/O) sector. For investors interested in the...
February 14, 2018

Pieris Pharmaceuticals Announces Public Offering of Common Stock

Pieris Pharmaceuticals (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other...
February 9, 2018

Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

Pieris Pharmaceuticals (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other...
December 7, 2017

Pieris Obtains Regulatory Clearance for Clinical Study in Australia

Pieris Pharmaceuticals announced it received approval from the Human Research Ethics Committee and authority from the Therapeutic Goods Administration to...